Philip B. Gorelick is a professor of translational science and molecular medicine at MSU and the emeritus medical director of the Hauenstein Neuroscience Center at Saint Mary’s Health Care in Grand Rapids, Michigan.
His work is centered around stroke prevention and identifying risk factors.
Gorelick has received nearly $40 million in research funding from the National Institutes of Health and has helped lead a clinical trial studying a new clot-busting drug for strokes. He has also worked with the American Heart Association offering guidance on preventing cognitive impairment and dementia by controlling risk factors for cardiovascular disease.
Industry Expertise (6)
Areas of Expertise (4)
Gainey Lectureship at Mayo Clinic (professional)
Awarded by the Mayo Clinic
Loyola University Chicago Stritch School of Medicine: MD, Medicine 1997
- US National Institute of Health
- Center for Medicare and Medicaid Services
AHA/ASA: Heart-healthy lifestyle also benefits brain health
Cardiology Today online
"“Research summarized in the advisory convincingly demonstrates that the same risk factors that cause atherosclerosis are also major contributors to late-life cognitive impairment and Alzheimer’s disease,” Philip B. Gorelick, MD, MPH, FAHA, executive medical director of Mercy Health Hauenstein Neurosciences in Grand Rapids, Michigan, and the chair of the advisory’s writing group, said in a press release. “By following seven simple steps — Life’s Simple 7 — not only can we prevent heart attack and stroke, we may also be able to prevent cognitive impairment..."
Journal Articles (3)
Robert J. Adams, Greg Albers, Mark J. Alberts, Oscar Benavente, Karen Furie, Larry B. Goldstein, Philip Gorelick, Jonathan Halperin, Robert Harbaugh, S. Claiborne Johnston, Irene Katzan, Margaret Kelly-Hayes, Edgar J. Kenton, Michael Marks, Ralph L. Sacco, Lee H. Schwamm
The American Heart Association/American Stroke Association (AHA/ASA) Writing Committee for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (TIA) has reviewed the results of recent trials that were published after our previous recommendations were issued.1 Our intention in the present statement is to provide a brief review of the new data, to update specific recommendations, and to provide the reasons for any modifications. The 2 areas in which major new clinical trials have been published are (1) the use of specific antiplatelet agents for stroke prevention in patients with a history of noncardioembolic ischemic stroke or TIA and (2) the use of statins in the prevention of recurrent stroke.
Philip B. Gorelick, Ka Sing Wong, Hee-Joon Bae, Dilip K. Pandey
Large artery intracranial occlusive disease (LAICOD) is a common and important stroke subtype. In this commentary, we review key epidemiological aspects of LAICOD.
Philip A. Wolf, G. Pat Clagett, J. Donald Easton, Larry B. Goldstein, Philip B. Gorelick, Margaret Kelly-Hayes, Ralph L. Sacco, Jack P. Whisnant
Stroke, the third leading cause of death in the United States, is a leading cause of adult neurological disability and accounts for the greatest number of hospitalizations for neurological disease. Although treatment of acute stroke has the potential of reducing death and disability, it is likely that prevention will more effectively reduce the ravages of stroke. The patient who is recovering from a mild stroke or who has had a recent transient ischemic attack (TIA) is at high risk of stroke recurrence, physical and intellectual disability, long-term institutionalization, and death.